Compare PRAX & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | TX |
|---|---|---|
| Founded | 2015 | 1961 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.5B |
| IPO Year | 2020 | 2006 |
| Metric | PRAX | TX |
|---|---|---|
| Price | $295.56 | $38.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $572.13 | $36.92 |
| AVG Volume (30 Days) | ★ 298.8K | 145.2K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 7.20% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.25 |
| Revenue Next Year | $6,395.88 | $6.86 |
| P/E Ratio | ★ N/A | $20.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.70 | $24.00 |
| 52 Week High | $354.87 | $45.57 |
| Indicator | PRAX | TX |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 37.84 |
| Support Level | $290.36 | $34.66 |
| Resistance Level | $322.32 | $38.99 |
| Average True Range (ATR) | 16.81 | 1.04 |
| MACD | -2.42 | -0.20 |
| Stochastic Oscillator | 26.09 | 27.17 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.